FC2 was shown to modulate the NF-κB pathway and induce cancer cell death in two human breast adenocarcinomas and in ovarian carcinoma cell lines, both as a single agent and in combination with known IAP antagonists or with the cytokine TNF. This evidence concerns the gene TNF and ovarian carcinoma.